Imunon (NASDAQ:IMNN) Announces Earnings Results, Misses Expectations By $0.09 EPS

Imunon (NASDAQ:IMNN) posted its earnings results on Thursday. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.09), FiscalAI reports.

Here are the key takeaways from Imunon’s conference call:

• Imunon said enrollment in its pivotal OVATION 3 trial is tracking to plan, averaging about 0.4 patients per active site per month versus a planning assumption of 0.3. The company is targeting 50% enrollment in Q1 2028, completion in Q1 2029, and a first interim analysis around Q1 2030, subject to trial execution.
• Management highlighted supportive clinical and safety findings for IMNN-001, including a 14.7-month median overall-survival difference in the earlier, not-powered-for-survival OVATION 2 study and promising biomarker and recurrence-free-survival signals in a 26-patient MRD study. The company stressed that these findings are not confirmatory and that OVATION 3 is the pivotal test.
• Imunon reported $4.0 million in cash and cash equivalents at quarter-end, plus $5.0 million in restricted cash, and $10.2 million in operating cash use for the first nine months of 2026. The company said additional capital is required to fund OVATION 3 and disclosed substantial doubt about its ability to continue as a going concern.
• The company is seeking to focus resources on OVATION 3 through an NCI collaboration to explore IMNN-001 in additional indications and a proposed ThermoDox transfer that could provide equity, milestones, and royalties. The ThermoDox deal depends on the partner completing a planned $2.5 million financing, and any resulting payments or value are uncertain.

Imunon Price Performance

Imunon stock traded down $0.08 during mid-day trading on Thursday, reaching $0.64. 2,183,609 shares of the company traded hands, compared to its average volume of 122,800. The company has a current ratio of 1.82, a quick ratio of 1.82 and a debt-to-equity ratio of 2.86. The firm’s fifty day moving average is $1.17 and its two-hundred day moving average is $2.12. Imunon has a fifty-two week low of $0.49 and a fifty-two week high of $4.38.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Imunon presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Imunon Company Profile

Imunon, Inc. (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing treatments for cancer and other serious diseases. The company uses proprietary nucleic acid delivery technologies to develop therapeutic candidates designed to stimulate the immune system or deliver genetic instructions directly to target cells. Imunon’s lead program is GEN-1, an investigational interleukin-12 gene-mediated immunotherapy intended to treat ovarian cancer. The company has evaluated GEN-1 in combination with chemotherapy and other treatments in clinical studies.